Disagreement in rivaroxaban dosing between Cockcroft–Gault and eGFR equations in nonvalvular atrial fibrillation: a statewide analysis

This publication has 24 references indexed in Scilit:

• Clinical outcomes of direct oral anticoagulant off-label dosing in nonvalvular atrial fibrillation
  Thrombosis Update, 2025
• Different Renal Function Equations and Dosing of Direct Oral Anticoagulants in Atrial Fibrillation
  JACC: Asia, 2022
• The Pharmacology, Efficacy, and Safety of Rivaroxaban in Renally Impaired Patient Populations
  The Journal of Clinical Pharmacology, 2021
• End-stage renal disease reduces the expression of drug-metabolizing cytochrome P450s
  Pharmacological Reports, 2020
• Effectiveness and Safety of Off-Label Dose-Reduced Direct Oral Anticoagulants in Atrial Fibrillation
  The American Journal of Medicine, 2019
• The Effects of CKD on Cytochrome P450–Mediated Drug Metabolism
  Advances in Chronic Kidney Disease, 2016
• Indexing Glomerular Filtration Rate to Body Surface Area: Clinical Consequences
  Journal of Clinical Laboratory Analysis, 2013
• Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban
  Clinical Pharmacokinetics, 2013
• Impact of Various Body Weights and Serum Creatinine Concentrations on the Bias and Accuracy of the Cockcroft‐Gault Equation
  Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2012
• Body surface area in normal-weight, overweight, and obese adults. A comparison study
  Metabolism, 2006